344 drugs passed the preliminary form of the national medical insurance drug catalog in 2022

Xinhua News Agency, Beijing, September 7th (Reporter Peng Yunjia) The National Medical Insurance Bureau recently publicized the preliminary review results of the national medical insurance catalog in 2022. A total of 344 medicines passed the preliminary form review, with a proportion of 70%. The number of censorship has increased from 2021. In terms of pass rate, the proportion of drugs outside the directory is 60%, and the proportion of drugs in the directory is 91%.

According to reports, the adjustment of medical insurance and drug catalogs is divided into aspects of corporate application, form review, expert review, negotiating bidding, etc. The formal review is only one of the links. Through form review, the drug is eligible to enter the next expert review session.

The State Medical Insurance Bureau prompts whether the drug can eventually enter the national medical insurance drug directory, which needs to be strictly reviewed in the multi -direction of the economy. The exclusive drugs that pass the review must be negotiated, and the non -exclusive drugs must be bidded. Integrated into the directory.

As of September 12, the National Medical Insurance Administration will further verify the relevant information based on the feedback received during the publicity period, determine the scope of the drug that is finally reviewed in form, and announce it to the society.

- END -